2008-08-11 16:25:07 -
- Investors: Javelin Pharmaceuticals, Inc. Rick Pierce, 617-499-4703 rpierce@javelinpharma.com or June Gregg, 617-499-4710 jgregg@javelinpharmaceuticals.com or Media: Richard Lewis Communications, Inc. Greg Tiberend, 212-827-0020 gtiberend@rlcinc.com or Megan Dubrowski, 212-827-0020 mdubrowski@rlcinc.com Javelin Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel products for pain management, today announced that chief executive officer Martin J. Driscoll, will provide a company overview at the 28th
Annual Canaccord Adams Global Growth Conference at 10:30 a.m. EDT on Thursday, August 14, 2008 at the InterContinental Hotel - 510 Atlantic Avenue, in Boston, MA.
The presentation will also be webcast and accessible live either by visiting the corporate Web site or through the following URL:
www.corporate-ir.net/ireye/conflobby.zhtml?ticker=JAV&item_id=1887 844 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
Listeners are advised to register in advance in order to download any necessary software. The event will be archived and available for 90 days.
About Javelin Pharmaceuticals, Inc.:
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has one marketed drug and three drug candidates in US Phase 3 clinical development. One of these US Phase 3 drug candidates, Dyloject(TM), has received Marketing Authorization Application (MAA) approval and favorable pricing in the UK, where it is now being sold. Previous clinical trials have demonstrated its safety and rapid onset of action. For additional information about Javelin, please visit the company's website at
www.javelinpharmaceuticals.com.
Forward Looking Statement:
This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.
JAV-G
Presentation to be Webcast
